Oral Antibiotics Market

The global oral antibiotics market generated $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, growing at a CAGR of 2.7% from 2019 to 2027.

Antibiotic is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections, but not viral infections. These are medications that either stop bacteria from growing or kill bacteria directly, referred as bacteriostatic and bactericidal antibiotics, respectively. There are several types of antibiotics easily available at drug stores and in hospitals with a prescription or without a prescription in most countries. Antibiotics are mostly used during transplants, dialysis, suppressed immune system, and joint replacement.

The virus that causes COVID-19 is from the family of viruses called Coronaviridae and antibiotics do not work against them. However, some people who are affected by Covid-19 can also develop a bacterial infection as a complication. In this case, health care providers recommend antibiotics. Hence, the impact of Covid-19 on oral antibiotics industry is expected to be moderate.

There is an increase in demand for antibiotics, owing to increased consumption in low- and middle-income countries (LMICs) and rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics to treat bacterial infections and large number of clinical trials further drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and time taken for regulatory approvals are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

The global oral antibiotics market is segmented on the basis of class, application, drug origin, spectrum of activity, drug type, and region. On the basis of class, it is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, and others. By application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental, and others. Depending on drug origin, it is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By drug type, it is divided into branded and generics. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the global oral antibiotics market include Abbott Laboratories, Allergan Plc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Segment review

Depending on class, the market is categorized into the beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018.  The segment is the major revenue contributor, owing to its broad-spectrum of activity. A broad-spectrum antibiotic fights both gram-negative and gram-positive bacteria as well as is effective on the multiple groups of bacterial infections. However, quinolone segment is expected to witness highest CAGRs during the forecast period, owing to its broad spectrum of activity and they are effective against a wide range of bacteria. 

On the basis of application, the CARTIs segment is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI). The dental segment is further divided into combination and monotherapies. The urinary acquired tract infections segment was the highest contributor to the market in 2018, and expected to witness CAGR of 2.0% during the forecast period, as it is the most common hospital acquired infection accounting for almost 40% of all nosocomial infections and females are more likely to acquire UTI every year as compared to males. In addition, diabetic patients are also more prone to UTIs, mostly owing to abnormalities in immune function.

On the basis of drug origin, the oral antibiotics market is classified into natural, semisynthetic and synthetic. The synthetic segment generated highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the fact that semisynthetic oral antibiotics have improved coverage and effectiveness against a wide range of organisms. However, the synthetic segment is projected to show fastest growth during the forecast period, due to the rising need of synthetic membrane-targeted antibiotics due to the antimicrobial resistance. The synthetic antibiotics have various advantages over existing antibiotics such as a broad spectrum of activity, no cross-resistance with the existing antibiotics, rapid bactericidal activity, and a low probability for developing resistance.

Region wise, Asia-Pacific accounted for nearly two-fifths of the global market share in 2018 and is expected to remain dominant throughout the forecast period. This region is the world’s largest consumer of antibiotics, owing to large number of antibiotics consumption, easy availability of antibiotics, and rise in sales of antibiotics without prescription. However, LAMEA is expected to experience the highest growth rate during the forecast period. This is attributed to easy obtainability of over-the-counter antibiotics as well as there are no legislations or restrictions on their use in this region.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the global oral antibiotics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers market analysis from 2018 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities. 
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global oral antibiotics market growth.

 Oral Antibiotics Market Report Highlights